BARDA head to discuss strategy at upcoming conference

Carol Linden

Carol Linden, the director of the Biomedical Advanced Research and Development Authority is expected to lay out the agency’s future strategy for protecting the public against bioterrorism at an upcoming conference in Washington.

Linden will speak about plans for the procurement of medical countermeasures under Project BioShield at the 10th Annual Biodefense Vaccines & Therapeutics Conference, to be held June 5-8 in the capital.

The meeting comes as the Pandemic All-Hazards Preparedness Act Reauthorization moves to conference committee following its unanimous approval in the Senate. The bill increases BARDA’s focus on the development of biodefense technology and provides $2.8 billion to Project BioShield for the purchase of medical countermeasures.

Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense at the U.S. Department of Defense Dr. Gerald Parker will be the keynote speaker at the conference.

Senior government representatives from the U.S. Centers for Disease Control and Prevention, the Defense Threat Reduction Agency, the Food and Drug Administration and the U.S. Army Medical Research Institute for Infectious Diseases will also be in attendance.

The conference is expected to provide a forum for debate over the federal government’s strategy for investing in prevention and preparedness against both bioterrorism and major infectious disease outbreaks.

Comments are closed.